The market is moving fast, and patients feel the gap
Private weight loss treatment in the UK has shifted from a niche service to a mainstream healthcare purchase. Demand is being driven by newer prescription medicines (particularly GLP-1 treatments) that can deliver meaningful, measurable results, but can also involve ongoing costs. That combination - high demand and higher out-of-pocket spend - is exactly where patient finance often enters the conversation.
UK data points to sustained growth. The UK prescription weight loss medicines market was around USD 421.07 million in 2025 and is projected to reach roughly USD 511.58 million in 2026. In England alone, 344,927 NHS patients were receiving licensed weight loss medications in early 2025, which also signals these treatments are now part of recognised clinical pathways.
At the same time, access is constrained. With waiting lists under pressure and weight management routes often tiered, many patients look to private providers when NHS routes are slow or unavailable. For a business, offering finance is not about pushing people into credit. Done properly, it is about giving customers a controlled, transparent way to spread the cost, with clear eligibility checks and the ability to say no when it would be unaffordable.
Who this guidance is designed for
This is for UK businesses that sell weight loss services or prescriptions privately and want to offer customers a way to pay over time. That includes clinics, online providers, pharmacies, and integrated health services offering consultation plus medication (for example semaglutide or tirzepatide) as part of a programme.
It is also relevant if you are not a lender and do not want to become one, but you do want to introduce customers to a finance provider in a compliant, responsible way. We will keep this practical and plain English: what options exist, what good looks like under UK rules, and the real-world risks to watch for when you are financing healthcare-related spending.
What it means to offer finance for weight loss treatments
In simple terms, offering finance means giving customers the option to spread the cost of a treatment plan instead of paying everything upfront. In the UK, this is usually done via a regulated credit provider, with your business acting as an introducer, credit broker, or merchant partner depending on the structure.
For weight loss treatments, finance can cover a range of costs, such as initial consultations, clinician follow-ups, membership-style programmes, and medication supply over a defined term. This matters because modern GLP-1 treatments have changed customer expectations on outcomes and therefore willingness to pay. For example, tirzepatide (often known by the brand Mounjaro) has shown up to 22.5% weight loss in trials over 72 weeks, compared with around 14.9% for semaglutide (Wegovy) in 68 weeks, and much lower average reductions for older options. In January 2026, the MHRA also approved a higher Wegovy 7.2 mg weekly dose for obesity, with STEP UP programme data indicating around 20% average weight loss.
Those results can make private treatment feel more worthwhile to patients, but they do not remove the need for careful budgeting and clear information. Finance should support informed choice, not override it.
How to set it up responsibly in the UK
Most UK providers do not become a lender themselves. Instead, they partner with an established finance provider and integrate an application journey into the clinic or checkout process. The best setup is straightforward for customers and robust behind the scenes.
A typical responsible approach looks like this:
- Decide what you are financing: consultation only, medication only, or a full programme over a defined duration.
- Choose your finance model: interest-free fixed instalments, interest-bearing instalments, or a regulated credit agreement through a third-party provider.
- Ensure clear, upfront pricing: total cost, deposit (if any), number of payments, APR (if applicable), and any fees.
- Build in affordability and eligibility checks: a lender will generally assess creditworthiness, but you still need to avoid encouraging customers to borrow if it is unsuitable.
- Train staff on compliant conversations: staff should explain options factually and avoid pressure, especially with healthcare purchases.
- Put customer support and complaints handling in place: customers need a clear route if something goes wrong.
If you act as a credit broker or make financial promotions, you may need FCA authorisation or to operate as an appointed representative, depending on the exact arrangement. Your finance partner should be able to explain the regulatory model and what you can and cannot say in marketing and on-site messaging.
Why finance is becoming a practical advantage, not a gimmick
Demand is real, and it is growing. A UCL-based estimate suggests around 1.6 million adults across England, Wales, and Scotland used weight loss drugs such as Wegovy and Mounjaro from early 2024 to early 2025. Most people taking medication solely for weight loss reported using Mounjaro. Importantly, a further 3.3 million people said they are interested in using these drugs over the next year. For any clinic planning capacity, retention, and customer experience, that pipeline matters.
Pressure on NHS access also shapes consumer behaviour. Projections suggest more than 60% of UK adults may be overweight or obese in 2026, while waiting lists remain high. Tiered weight management services and specialist routes can involve long delays, and obesity-linked interventions can have significant waits too. In that context, private providers can offer faster access, but customers still need a manageable way to pay.
For a business, finance can reduce drop-off at checkout, help customers commit to a planned course (rather than stop-start purchasing), and improve predictability of revenue. For customers, it can provide budgeting clarity. The key is that it must be done with transparency and safeguards, because borrowing for healthcare should never be treated casually.
Pros and cons at a glance
| Aspect | Pros | Cons |
|---|---|---|
| Customer affordability | Spreads cost into predictable payments, potentially improving access to private care | Credit is still debt and can worsen financial stress if repayments are unaffordable |
| Business conversions | Can reduce upfront price friction and increase uptake of full programmes | If mis-sold or poorly explained, can trigger complaints and reputational harm |
| Treatment adherence | Budgeting stability may support consistent follow-ups and continuity | Customers may continue paying even if they stop treatment early, depending on terms |
| Compliance and trust | Working with regulated partners can raise confidence and standardise checks | Adds regulatory complexity, training needs, and tighter controls on marketing claims |
| Cashflow | Depending on the model, you may be paid upfront by the finance provider | Fees and merchant charges can reduce margin and require careful pricing |
| Future innovation | Supports longer plans as newer options emerge (for example next-gen medicines) | Rapid product changes can create confusion if finance terms are not clearly linked to what is included |
Things to look out for before you launch
Because this sits at the intersection of healthcare and credit, the biggest risks are usually about clarity, suitability, and expectations.
First, be precise about what the customer is buying. Weight loss treatment is rarely a one-off purchase. If the finance agreement covers a 6 or 12 month programme, make sure customers understand what is included (consultations, monitoring, prescriptions, delivery fees) and what is not included.
Second, keep outcomes honest. Newer medicines can deliver substantial average reductions, but results vary and side effects exist. Avoid implying guaranteed weight loss, and make sure clinical eligibility and prescribing decisions remain separate from the finance decision.
Third, be careful with how you present urgency. NHS waits and service constraints are real, but marketing should never suggest a customer must borrow to avoid harm, or that credit approval is likely for everyone.
Fourth, plan for change. With innovation continuing, customers may ask about switching. Retatrutide, for example, has shown up to 28.7% average weight loss in trials and is expected to progress toward regulatory submission in 2026. That can increase interest in longer-term plans, but it also means you need clear policies on treatment changes, refunds, cancellations, and what happens if a medicine is unsuitable.
Good finance is quiet and clear: customers understand the cost, the commitment, and their right to step back.
Alternatives to offering customer finance
- Transparent pay-as-you-go pricing with no credit option.
- Treatment bundles with a small discount for upfront payment.
- Monthly subscription model where customers can pause or cancel, subject to clinical safety.
- Deposit-based booking with staged payments before each supply cycle.
- Employer-funded wellbeing partnerships for eligible workforces.
- Signposting to NHS pathways and local weight management services for customers who prefer public routes.
- Savings-first options, such as allowing customers to prepay into an account before treatment begins.
FAQs customers and clinics ask most
Sometimes. If you are introducing customers to a lender or promoting credit, you may be carrying out regulated credit broking. Many businesses operate via an authorised partner or as an appointed representative, but you should confirm the exact model with compliance support.
Can we advertise “0% finance” on weight loss programmes?
You can, but only if it is accurate and the advertising is compliant. Customers must see key information clearly, including any deposit, the number of instalments, and what happens if they miss payments.
How do affordability checks work?
The lender typically carries out creditworthiness and affordability checks as part of the application. Your role is to avoid pressure selling, present options fairly, and ensure staff do not steer someone toward borrowing if they are unsure.
Is demand really strong enough to justify finance?
UK indicators suggest it is. Around 1.6 million adults used weight loss drugs in the year to early 2025, and a further 3.3 million expressed interest in using them over the next year. Market forecasts also point to continued growth through 2026.
Will customers finance higher-dose or newer options?
Many will consider it if the value is clear and budgeting is manageable. The MHRA approval of higher-dose Wegovy (7.2 mg) and strong trial results for tirzepatide can increase interest, but finance must still be offered responsibly.
What if a customer stops treatment early?
This depends on your clinical policy and the credit agreement. Customers should be told upfront whether finance continues, whether refunds are possible, and how cancellations work.
Does offering finance increase complaints risk?
It can if terms are unclear or conversations are rushed. Clear documentation, staff training, and a straightforward complaints process help reduce problems.
How Switcha can help
As a UK price comparison website, Switcha can help you understand and compare the building blocks around offering finance, from payment options and provider features to the total cost customers actually pay over time. We focus on clear, factual comparisons so you can choose a setup that fits your business model and supports customers in making informed, affordable decisions.
We also help you sense-check messaging so it stays transparent and responsible, especially important where healthcare and borrowing overlap.
Important information
This article is general information for UK businesses and is not financial, legal, or medical advice. Regulation depends on how you structure finance and how you promote it, so take professional advice before launching. Weight loss medicines are prescription-only and must be provided under appropriate clinical oversight. Customers should be encouraged to consider affordability carefully and to seek independent guidance if they are unsure about taking on credit.
